Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial.
Adaptation, Psychological
Adolescent
Adult
Advance Care Planning
Advance Directives
Aged
Aged, 80 and over
Belgium
Communication
Decision Making
/ physiology
Denmark
Female
Humans
Italy
Male
Middle Aged
Neoplasms
/ diagnosis
Netherlands
Patient Participation
/ statistics & numerical data
Patient-Centered Care
Quality of Life
/ psychology
Slovenia
United Kingdom
Young Adult
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
26
02
2020
accepted:
19
10
2020
entrez:
13
11
2020
pubmed:
14
11
2020
medline:
26
1
2021
Statut:
epublish
Résumé
Advance care planning (ACP) supports individuals to define, discuss, and record goals and preferences for future medical treatment and care. Despite being internationally recommended, randomised clinical trials of ACP in patients with advanced cancer are scarce. To test the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia, and United Kingdom in 2015-2018. Patients with advanced lung (stage III/IV) or colorectal (stage IV) cancer, WHO performance status 0-3, and at least 3 months life expectancy were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in the intervention arm included scripted ACP conversations between patients, family members, and certified facilitators; standardised leaflets; and standardised advance directives. Control patients received care as usual. Main outcome measures were quality of life (operationalised as European Organisation for Research and Treatment of Cancer [EORTC] emotional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient involvement in decision-making, inclusion of advance directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included (442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire. Patients' age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of patients found ACP conversations distressing. Mean change in patients' quality of life did not differ between intervention and control groups (T-score -1.8 versus -0.8, p = 0.59), nor did changes in symptoms, coping, patient satisfaction, and shared decision-making. Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p < 0.001) were more likely in the intervention group. A key limitation of the study is that recruitment rates were lower in intervention than in control hospitals. Our results show that quality of life effects were not different between patients who had ACP conversations and those who received usual care. The increased use of specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful and requires further study. Our findings suggest that alternative approaches to support patient-centred end-of-life care in this population are needed. ISRCTN registry ISRCTN63110516.
Sections du résumé
BACKGROUND
Advance care planning (ACP) supports individuals to define, discuss, and record goals and preferences for future medical treatment and care. Despite being internationally recommended, randomised clinical trials of ACP in patients with advanced cancer are scarce.
METHODS AND FINDINGS
To test the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia, and United Kingdom in 2015-2018. Patients with advanced lung (stage III/IV) or colorectal (stage IV) cancer, WHO performance status 0-3, and at least 3 months life expectancy were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in the intervention arm included scripted ACP conversations between patients, family members, and certified facilitators; standardised leaflets; and standardised advance directives. Control patients received care as usual. Main outcome measures were quality of life (operationalised as European Organisation for Research and Treatment of Cancer [EORTC] emotional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient involvement in decision-making, inclusion of advance directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included (442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire. Patients' age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of patients found ACP conversations distressing. Mean change in patients' quality of life did not differ between intervention and control groups (T-score -1.8 versus -0.8, p = 0.59), nor did changes in symptoms, coping, patient satisfaction, and shared decision-making. Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p < 0.001) were more likely in the intervention group. A key limitation of the study is that recruitment rates were lower in intervention than in control hospitals.
CONCLUSIONS
Our results show that quality of life effects were not different between patients who had ACP conversations and those who received usual care. The increased use of specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful and requires further study. Our findings suggest that alternative approaches to support patient-centred end-of-life care in this population are needed.
TRIAL REGISTRATION
ISRCTN registry ISRCTN63110516.
Identifiants
pubmed: 33186365
doi: 10.1371/journal.pmed.1003422
pii: PMEDICINE-D-20-00632
pmc: PMC7665676
doi:
Banques de données
ISRCTN
['ISRCTN63110516']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003422Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: BH and LB are developers of Respecting Choices and report personal fees from Gundersen Health, outside the submitted work.
Références
Stat Med. 2014 Sep 20;33(21):3601-28
pubmed: 24889022
J Pain Symptom Manage. 2019 Jun;57(6):1071-1079.e1
pubmed: 30794935
Lancet Oncol. 2017 Sep;18(9):e543-e551
pubmed: 28884703
Palliat Med. 2019 Jan;33(1):5-23
pubmed: 30362897
J Am Geriatr Soc. 2018 Jul;66(6):1089-1095
pubmed: 29608789
Palliat Med. 2018 May;32(5):990-1009
pubmed: 29485314
Palliat Med. 2014 Sep;28(8):1000-25
pubmed: 24651708
J Pers Soc Psychol. 2000 Jun;78(6):1150-69
pubmed: 10870915
Palliat Med. 2016 Jun;30(6):533-48
pubmed: 26577927
J Pain Symptom Manage. 2018 Aug;56(2):169-177.e1
pubmed: 29729347
Support Care Cancer. 2020 Mar;28(3):1513-1522
pubmed: 31278462
CMAJ. 1995 May 1;152(9):1423-33
pubmed: 7728691
JAMA. 2008 Oct 8;300(14):1665-73
pubmed: 18840840
Eur J Cancer. 2019 Jan;107:133-141
pubmed: 30576969
J Clin Oncol. 2013 Sep 20;31(27):3403-10
pubmed: 23897967
J Clin Epidemiol. 2016 Feb;70:90-100
pubmed: 26363341
J Pain Symptom Manage. 2012 Apr;43(4):739-46
pubmed: 22464353
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
Arch Intern Med. 2002 Jul 22;162(14):1611-8
pubmed: 12123405
J Pain Symptom Manage. 2018 Sep;56(3):436-459.e25
pubmed: 29807158
Biostatistics. 2018 Oct 1;19(4):407-425
pubmed: 29028922
JAMA Oncol. 2018 Dec 1;4(12):1736-1741
pubmed: 30326035
Palliat Med. 2018 Sep;32(8):1305-1321
pubmed: 29956558
Palliat Support Care. 2011 Mar;9(1):3-13
pubmed: 21352613
Patient Educ Couns. 2009 Dec;77(3):404-12
pubmed: 19892508
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Pers Soc Psychol. 1989 Feb;56(2):267-83
pubmed: 2926629
Eur J Cancer. 2006 Jan;42(1):55-64
pubmed: 16162404
J Pain Symptom Manage. 2018 Feb;55(2):245-255.e8
pubmed: 28865870
J Am Med Dir Assoc. 2014 Jul;15(7):477-489
pubmed: 24598477
JAMA Intern Med. 2019 Jun 1;179(6):751-759
pubmed: 30870563
BMJ. 2010 Mar 23;340:c1345
pubmed: 20332506
Br J Cancer. 2018 Nov;119(10):1182-1190
pubmed: 30369600
BMC Cancer. 2016 Apr 08;16:264
pubmed: 27059593
Eur J Cancer. 2005 Sep;41(14):2120-31
pubmed: 16182120
Stat Med. 2008 Jul 30;27(17):3227-46
pubmed: 18203127
J Palliat Med. 2018 Mar;21(S2):S17-S27
pubmed: 29091522
Value Health. 2019 Jan;22(1):92-98
pubmed: 30661639
Thorax. 2018 Mar;73(3):222-230
pubmed: 29109233
BMC Med Ethics. 2019 Mar 4;20(1):17
pubmed: 30832644